Combination treatment with BRAF (vemurafenib, dabrafenib or encorafenib) and downstream MEK (trametinib or binimetinib) inhibitors is recommended for patients with advanced BRAF-mutant melanoma [5–7]. This evidence concerns the gene BRAF and melanoma.